The U.S. precision medicine market size is calculated at USD 58.09 billion in 2025 and is predicted to reach around USD 232.49 billion by 2034, accelerating at a CAGR of 16.66% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
7.1. U.S. Precision Medicine Market Revenue and Volume, by Technology
7.1.1. Bioinformatics
7.1.1.1. Market Revenue and Volume Forecast
7.1.2. Big Data Analytics
7.1.2.1. Market Revenue and Volume Forecast
7.1.3. Drug Discovery
7.1.3.1. Market Revenue and Volume Forecast
7.1.4. Gene Sequencing
7.1.4.1. Market Revenue and Volume Forecast
7.1.5. Companion Diagnostics
7.1.6.1. Market Revenue and Volume Forecast
7.1.6. Others
7.1.5.1. Market Revenue and Volume Forecast
8.1. U.S. Precision Medicine Market Revenue and Volume, by Application
8.1.1. CNS
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Immunology
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Oncology
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Respiratory
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Volume Forecast
9.1. U.S. Precision Medicine Market Revenue and Volume, by End-Use
9.1.1. Diagnostic Companies
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Pharmaceutical Companies
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Healthcare IT companies
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Others
9.1.4.1. Market Revenue and Volume Forecast
10.1. U.S. Precision Medicine Market Revenue and Volume, by Sequencing Technology
10.1.1. Sequencing by Synthesis
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Ion Semiconductor Sequencing
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Sequencing by Ligation
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Pyrosequencing
10.1.4.1. Market Revenue and Volume Forecast
10.1.5. Single Molecule Real Time Sequencing
10.1.5.1. Market Revenue and Volume Forecast
10.1.6. Chain Termination Sequencing
10.1.6.1. Market Revenue and Volume Forecast
10.1.7. Nanopore Sequencing
10.1.7.1. Market Revenue and Volume Forecast
11.1. U.S. Precision Medicine Market Revenue and Volume, by Product
11.1.1. Consumables
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Instruments
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Services
11.1.3.1. Market Revenue and Volume Forecast
12.1. U.S. Precision Medicine Market Revenue and Volume, by Route of Administration
12.1.1. Oral
12.1.1.1. Market Revenue and Volume Forecast
12.1.2. Injectable
12.1.2.1. Market Revenue and Volume Forecast
13.1. U.S. Precision Medicine Market Revenue and Volume, by Drugs
13.1.1. Alectinib
13.1.1.1. Market Revenue and Volume Forecast
13.1.2. Osimertinib
13.1.2.1. Market Revenue and Volume Forecast
13.1.3. Mepolizumab
13.1.3.1. Market Revenue and Volume Forecast
13.1.4. Aripiprazole Lauroxil
13.1.4.1. Market Revenue and Volume Forecast
13.1.5. Others
13.1.5.1. Market Revenue and Volume Forecast
14.1. U.S.
14.1.1. Market Revenue and Volume Forecast, by Technology
14.1.2. Market Revenue and Volume Forecast, by Application
14.1.3. Market Revenue and Volume Forecast, by End-Use
14.1.4. Market Revenue and Volume Forecast, by Sequencing Technology
14.1.5. Market Revenue and Volume Forecast, by Product
14.1.6. Market Revenue and Volume Forecast, by Drugs
14.1.7. Market Revenue and Volume Forecast, by Route of Administration
15.1. Biocrates Life Sciences
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Quest Diagnostics
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. NanoString Technologies
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Pfizer
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. AbbVie Inc.
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. AstraZeneca
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Johnson & Johnson Services, Inc
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Thermo Fisher Scientific, Inc.
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Illumina, Inc.
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. ARIEL Precision Medicine, Inc.
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample